JP2009235086A5 - - Google Patents

Download PDF

Info

Publication number
JP2009235086A5
JP2009235086A5 JP2009139245A JP2009139245A JP2009235086A5 JP 2009235086 A5 JP2009235086 A5 JP 2009235086A5 JP 2009139245 A JP2009139245 A JP 2009139245A JP 2009139245 A JP2009139245 A JP 2009139245A JP 2009235086 A5 JP2009235086 A5 JP 2009235086A5
Authority
JP
Japan
Prior art keywords
salt
valsartan
pharmaceutically acceptable
acceptable salt
calcium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009139245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009235086A (ja
JP5303370B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009235086A publication Critical patent/JP2009235086A/ja
Publication of JP2009235086A5 publication Critical patent/JP2009235086A5/ja
Application granted granted Critical
Publication of JP5303370B2 publication Critical patent/JP5303370B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2009139245A 2002-02-04 2009-06-10 バルサルタンの塩類 Expired - Fee Related JP5303370B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35419902P 2002-02-04 2002-02-04
US60/354,199 2002-02-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003565980A Division JP4895475B2 (ja) 2002-02-04 2003-02-03 バルサルタンの塩類

Publications (3)

Publication Number Publication Date
JP2009235086A JP2009235086A (ja) 2009-10-15
JP2009235086A5 true JP2009235086A5 (US07585860-20090908-C00112.png) 2010-07-29
JP5303370B2 JP5303370B2 (ja) 2013-10-02

Family

ID=27734333

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003565980A Expired - Fee Related JP4895475B2 (ja) 2002-02-04 2003-02-03 バルサルタンの塩類
JP2009139245A Expired - Fee Related JP5303370B2 (ja) 2002-02-04 2009-06-10 バルサルタンの塩類

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003565980A Expired - Fee Related JP4895475B2 (ja) 2002-02-04 2003-02-03 バルサルタンの塩類

Country Status (18)

Country Link
US (3) US6869970B2 (US07585860-20090908-C00112.png)
EP (1) EP1474402A1 (US07585860-20090908-C00112.png)
JP (2) JP4895475B2 (US07585860-20090908-C00112.png)
KR (3) KR20110101257A (US07585860-20090908-C00112.png)
CN (2) CN100548993C (US07585860-20090908-C00112.png)
AU (1) AU2003214054B2 (US07585860-20090908-C00112.png)
BR (1) BR0307442A (US07585860-20090908-C00112.png)
CA (2) CA2474424C (US07585860-20090908-C00112.png)
CO (1) CO5611107A2 (US07585860-20090908-C00112.png)
EC (1) ECSP045221A (US07585860-20090908-C00112.png)
HK (1) HK1139681A1 (US07585860-20090908-C00112.png)
MX (1) MXPA04007525A (US07585860-20090908-C00112.png)
NO (1) NO328155B1 (US07585860-20090908-C00112.png)
NZ (1) NZ534560A (US07585860-20090908-C00112.png)
PL (1) PL370481A1 (US07585860-20090908-C00112.png)
RU (1) RU2004126862A (US07585860-20090908-C00112.png)
WO (1) WO2003066606A1 (US07585860-20090908-C00112.png)
ZA (1) ZA200405698B (US07585860-20090908-C00112.png)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
SI1515717T1 (sl) * 2002-06-13 2009-02-28 Novartis Ag Kalcijeve soli statinov, izvedenih iz indola
DE602004013405T2 (de) * 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
JP4783733B2 (ja) * 2003-05-16 2011-09-28 ノバルティス アーゲー バルサルタンを含む医薬組成物
WO2005046677A2 (en) * 2003-11-14 2005-05-26 Novartis Ag At1-receptor antagonists for treating nephrotic syndrome
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
DE502004002443D1 (de) * 2004-04-15 2007-02-08 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
AR061627A1 (es) 2006-06-27 2008-09-10 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Arb及び/又はグリタゾン系血糖降下物質を含有するoatp−r遺伝子発現増強組成物
MX2013001251A (es) 2010-08-03 2013-03-18 Novartis Ag Valsartan altamente cristalino.
CN103012301B (zh) * 2013-01-05 2015-06-17 江苏施美康药业股份有限公司 缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59107440D1 (de) * 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
ES2099031B1 (es) 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
AP9901660A0 (en) * 1997-02-28 1999-09-30 Burstein Lab Inc Laboratory in a disk.
US6641886B1 (en) * 1999-03-23 2003-11-04 Flexplay Technologies, Inc. Directory read inhibitor for optical storage media
JP2001155346A (ja) * 1999-11-26 2001-06-08 Toshiba Corp 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
HUP0300701A2 (hu) 2000-04-24 2003-07-28 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartarát, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
PE20020613A1 (es) 2000-07-19 2002-08-07 Novartis Ag Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Similar Documents

Publication Publication Date Title
JP2009235086A5 (US07585860-20090908-C00112.png)
RU2004126862A (ru) Соли валсартана
JP2005517696A5 (US07585860-20090908-C00112.png)
JP2012067131A5 (US07585860-20090908-C00112.png)
RU2009136593A (ru) Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у илекопитаюших
CA2415962A1 (en) Valsartan salts
JP2011168587A5 (US07585860-20090908-C00112.png)
RU2003104789A (ru) Соли валсартана
HRP20151299T1 (hr) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
JP2007532560A5 (US07585860-20090908-C00112.png)
RU2466129C2 (ru) Твердые формы рацемического илапразола
RU2008141373A (ru) Соль алискирена и серной кислоты
CA2632283A1 (en) Polymorphs of a c-met/hgfr inhibitor
JP2012507476A5 (US07585860-20090908-C00112.png)
JP2009502780A5 (US07585860-20090908-C00112.png)
JP2012512885A5 (US07585860-20090908-C00112.png)
JP2010514806A5 (US07585860-20090908-C00112.png)
JP2012501296A5 (US07585860-20090908-C00112.png)
JP2009517353A5 (US07585860-20090908-C00112.png)
JP2013538849A5 (US07585860-20090908-C00112.png)
JP2009531465A5 (US07585860-20090908-C00112.png)
SI2016051T1 (sl) Beta-kristalna oblika argininske soli perindoprila, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
Khandavilli et al. High solubility crystalline hydrates of Na and K furosemide salts
JP2013523706A5 (US07585860-20090908-C00112.png)
WO2017092703A1 (zh) 制备无定型奥贝胆酸的方法